Plain-English translation of NCT07158164 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Neoplasms research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a genetic test can help doctors give you the right dose of fluoropyrimidine chemotherapy for your cancer. Some people's bodies break down this medication slowly because of differences in their genes, which can lead to serious side effects. This study checks whether giving a lower dose to people with these genetic differences keeps them safer while still treating their cancer effectively.
Fluoropyrimidine chemotherapy has been used for decades, but doctors have struggled to find the right dose because different patients experience very different side effects from the same amount of medication. About 2-4% of people have genetic variations that slow how their body processes the medication, putting them at risk for severe toxicity. This trial aims to see whether a simple genetic test before treatment can prevent dangerous side effects by personalizing the dose.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first have a genetic test to check your DPYD gene status. Based on your results, you will either receive standard chemotherapy doses (if you have normal genes) or a reduced dose for your first two cycles (if you have one genetic variant). Your doctor will monitor you closely for side effects during treatment and may adjust your dose further if needed. The study will track how well the treatment works and whether personalized dosing reduces harmful side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States